Fulcrum’s Pociredir Collapse: How FDA’s PRC2 Risk View Crushed a Data-Rich Sickle Cell Drug

The Surface News

Fulcrum announced the discontinuation of pociredir for sickle cell disease after receiving FDA meeting minutes from recent end-of-phase interactions on May 28, 2026. The company said FDA’s feedback reflected heightened concern about the benefit-risk profile of pociredir in sickle cell disease.

The trigger was Tazverik, also known as tazemetostat, another PRC2 inhibitor. Tazverik had been withdrawn globally after an unexpectedly high rate of hematologic second primary malignancies was observed.

Fulcrum tried to separate pociredir from Tazverik mechanistically. Pociredir targets EED, while Tazverik targets EZH2. Both are within the PRC2 complex, but Fulcrum argued that the different subunits and biological roles should matter in the benefit-risk analysis.

The FDA considered the argument, but according to Fulcrum, concluded that pharmacological intervention against the PRC2 complex carries equivalent malignancy risk regardless of which subunit is engaged.

That sentence is the center of this story. For investors, the FDA was not only looking at the molecule. It was looking at the biological neighborhood.

The Data Contradiction

The strongest version of this story begins with the contradiction between pociredir’s early efficacy data and the final regulatory outcome. Pociredir’s 20 mg cohort did not look like a weak asset. The dataset was early and small, but directionally strong across multiple disease-relevant markers.

This is why the market reaction was so severe. Fulcrum was not discontinuing a drug after a conventional efficacy miss. It was discontinuing a drug after FDA’s target-class safety logic overwhelmed a package that had looked strong enough for a planned late-stage discussion. Alex C. Sapir, Fulcrum’s CEO, had previously framed the 20 mg data as reinforcing confidence in pociredir’s potential. Dr. Martin Steinberg of Boston University had linked the HbF induction and F-cell rise to the possibility of altering the disease’s underlying pathophysiology. A few months later, the drug had no viable regulatory path. That is not a normal clinical-development arc.

The Tazverik Safety Bomb

The reason FDA moved hard is visible in the Tazverik data. Tazverik was approved under accelerated approval in 2020 for certain patients with epithelioid sarcoma and later for follicular lymphoma. FDA later alerted providers and patients that the sponsor would voluntarily withdraw the product because hematologic second primary malignancies had increased.

In the SYMPHONY-1 trial, 18 of 318 patients treated with Tazverik developed hematologic second primary malignancies. That was 5.7%. The control arm had zero reported cases. The earlier recognized incidence was 1.7%, but the newer trial showed the rate exceeding 5% over a median treatment duration of 15.8 months.

The malignancy types were not trivial. FDA described myelodysplastic syndrome and acute myeloid leukemia as the most common, with other events including B-cell acute lymphoblastic leukemia and clonal cytopenia of undetermined significance. Severity made the signal harder to ignore. FDA noted three deaths among the 18 patients and 14 patients without resolution of the hematologic second primary malignancy.

This was not a mild tolerability issue. It was a blood cancer signal.

Why FDA’s Logic Hit Pociredir Harder Than the Data Suggested

In oncology, regulators sometimes tolerate serious risk if the disease is aggressive, treatment options are limited, and potential benefit is large. Sickle cell disease also carries high unmet need, but the benefit-risk calculation is different.

Pociredir was being developed as a chronic oral therapy for a non-cancer population. Patients could potentially be treated for long periods. Some may be young adults. The disease is severe, but the therapy would not be used in the same risk context as late-line oncology.

A malignancy signal that may be tolerated differently in cancer becomes much harder to defend in a chronic non-oncology disease. This is why the indication mattered as much as the mechanism.

The Hidden History: This Was Not the First PRC2 Warning

The 2026 discontinuation did not come from nowhere. In February 2023, FDA had already placed the IND for FTX-6058, the earlier name for pociredir, on clinical hold. Fulcrum later announced the hold was lifted in August 2023. The company said FDA had noted preclinical data submitted in 2022 and non-clinical and clinical evidence of hematologic malignancies observed with other PRC2 inhibitors.

This point is important. The PRC2 concern was not new. It had already interrupted development once. The difference in 2026 was that Tazverik’s real-world regulatory situation had become much more severe. A class concern that had once been manageable enough to lift a clinical hold became strong enough, after Tazverik’s withdrawal and the FDA meeting minutes, to remove the pathway altogether.

So this was not only a sudden regulatory reversal. It was the return of an unresolved biological-risk question.

The Financial Shock

The stock market understood the difference between a delay and a dead path. Fulcrum shares fell 52% after the announcement, according to Reuters. Barron’s reported a 54% fall, taking the stock to $2.98.

Analysts also reset expectations quickly. H.C. Wainwright cut its rating from Buy to Neutral and reduced its price target from $25 to $3. Truist cut its rating to Hold and reduced its target to $4.

These were not normal target-price trims. They were valuation resets. Fulcrum still had cash. As of March 31, 2026, the company reported $333.3 million in cash, cash equivalents and marketable securities. In April, the company had said its cash runway extended into 2029.

That is why this case is important for biotech investing. Fulcrum did not run out of cash. It ran out of regulatory permission to convert its data into value. That is a very different failure mode.

The Sickle Cell Context + Oxbryta Shadow

The failure hurts more because sickle cell disease still needs scalable therapies. WHO estimated that 7.74 million people were living with sickle cell disease globally in 2021, with 515,000 new births that year. CDC estimates about 100,000 people in the United States live with sickle cell disease, with life expectancy more than 20 years shorter than average.

The clinical burden is heavy: anemia, acute pain crises, infections, stroke, organ damage, kidney disease, liver disease, heart disease and reduced life expectancy.

This is why an oral HbF inducer mattered. Gene therapies have changed the scientific conversation, but they are complex, expensive, intensive and not necessarily scalable for every patient. Hydroxyurea remains important, but gaps in uptake and response remain. Regular transfusions can help selected patients, but they carry burden and complications.

An oral drug that could raise fetal hemoglobin meaningfully, improve hemolysis markers and potentially reduce crises would have filled a valuable middle ground between older disease-modifying care and highly complex curative interventions.

Pociredir was not trying to be another symptom-control medicine. It was trying to reopen fetal hemoglobin biology through PRC2 modulation. That promise is exactly what made the regulatory risk more painful.

Fulcrum’s setback also landed in a sickle-cell field that had already absorbed another major safety blow. In 2024, Pfizer withdrew Oxbryta from all markets, citing risks involving vaso-occlusive crises and deaths. Pfizer had acquired Oxbryta through its $5.4 billion buyout of Global Blood Therapeutics in 2022. The drug had generated $328 million in 2023 revenue.

That withdrawal already damaged confidence in the sickle-cell drug category. Oxbryta and pociredir are very different drugs, but investors read patterns. Two high-profile safety-driven setbacks in sickle cell disease, one from an approved therapy and another from an investigational oral program, reinforce a difficult message: the field has huge need, but the regulatory and safety bar is unforgiving.

The Real Break: Regulatory Contagion

This is the concept Witfire should own in the story: regulatory contagion. Regulatory contagion happens when a safety problem from one product spreads across a target class, mechanism, platform, modality or biological pathway, even when another company’s drug has different chemistry or a different clinical setting.

That is what happened here. Tazverik was an oncology drug. Pociredir was a sickle-cell drug. Tazverik targeted EZH2. Pociredir targeted EED. Tazverik had observed hematologic second primary malignancies. Pociredir had reported no new clinical safety signal at the cutoff cited by Fulcrum. Still, the common PRC2 connection was enough for FDA to treat the malignancy concern as a broader class issue.

The drug you are not developing can still affect the drug you are developing. That is the lesson.

Why the FDA May Have Been Reluctant to Separate EED From EZH2

Fulcrum’s mechanistic argument was not irrational. EED and EZH2 are not identical targets. They perform different roles within PRC2 biology. In theory, that difference could matter.

But regulators are not obligated to accept target-subunit separation when the downstream biological complex is connected to a severe safety concern. From FDA’s perspective, the key question may not have been whether pociredir and Tazverik bind identical proteins. The question may have been whether chronic PRC2 pathway intervention could plausibly create malignancy risk in humans.

If the answer is yes, then a subunit distinction may be too narrow to rescue the program, especially in sickle cell disease. This is the harsh regulatory reality. Mechanistic differentiation is valuable only if the regulator believes the differentiation changes patient risk. Fulcrum could explain the difference. It could not, based on the outcome, make the FDA comfortable enough with the risk.

The Investor Lesson + CEO Lesson

The usual checklist is not enough: Does the drug work? Is the endpoint meaningful? Is cash runway adequate? Is the trial design clear? Is the unmet need large? All of that matters. But this case adds another layer: Has the broader target class produced a severe safety signal anywhere else? Has FDA already shown concern about the mechanism? Could a different drug in a different indication contaminate the program’s benefit-risk profile? Is the product intended for chronic use in a non-oncology population? Can the company prove that its subunit, binding site or pathway effect is meaningfully safer?

Pociredir would have looked stronger if judged only on HbF induction. It looked much weaker once judged through PRC2 class-risk logic. That is why the valuation broke.